Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 18,078	$ 14,776
Short-term investments	26,349	16,615
Prepaid expenses and other current assets	650	574
Total current assets	45,077	31,965
Property and equipment, net	880	756
Investment in OvaXon	1,500
Restricted cash	88	93
Total assets	47,545	32,814
Current liabilities:
Accounts payable	1,654	875
Accrued expenses	4,120	1,211
Total current liabilities	5,774	2,086
Other non-current liabilities	70	7
Total liabilities	5,844	2,093
Commitments and contingencies (Note 11)
Stockholder's equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 18,528,215 and 14,268,068 shares issued at December 31, 2013 and December 31, 2012, respectively; 17,541,126 and 12,622,919 shares outstanding at December 31, 2013 and December 31, 2012, respectively	18	13
Additional paid-in capital	86,851	46,848
Accumulated other comprehensive income/(loss)	10	(6)
Deficit accumulated during the development stage	(45,178)	(16,134)
Total stockholders' equity	41,701	30,721
Total liabilities and stockholders' equity	$ 47,545	$ 32,814